April 20, 2025
avatar-torie-bosch
First Opinion editor

On the First Opinion Podcats — sorry, I mean Podcast — this week, I spoke with a veterinarian and epidemiologist about how felines could play a pivotal role in an expanded avian flu crisis. Meghan Davis of Johns Hopkins University told me that she has recently stopped letting her own cats (she wouldn’t say how many she has) onto their outdoor “catio” because H5N1 bird flu had been found in her area. She didn’t want to risk that bird droppings could infect her pets. Cats, it turns out, are highly susceptible to bird flu.

I’ve mentioned before that I’d love more veterinary medicine coverage in First Opinion, and Meghan’s interview — plus her previous First Opinion essays on surveilling pets for infectious disease and on the dangers of gutting the National Institute for Occupational Safety and Health — reminded me why. It’s not just that so many of us love our pets and want to keep them healthy. It’s that we’re all deeply intertwined. Just as human workers on dairy farms have been infected with bird flu, so too have barn cats. And the more the virus passes between species, the riskier things get.

So keep those submissions about veterinary medicine — the money, the regulation, and the effect on human health — coming.

Recommendation of the week: I’m grateful to Bravo for distracting me from the news for an hour each week with “Summer House,” in which gorgeous people drink too much, gossip, and never discuss politics (except for one time, and it was honestly pretty good). One cast member recently had a baby with her biotech investor boyfriend, who I must assume is a STAT reader and STAT+ subscriber. New dream First Opinion assignment: how reality TV is like biotech.



Adobe

I don’t know what I’m supposed to call my rare kidney disease

I don't know my disease's name definitively, and it’s not because my diagnosis changed. It’s become the subject of intense debate.

By Taylor Coffman


Five priorities to remake the FDA in a time of deep uncertainty  

Respect review teams, modernize post-market product evaluation, and three other priorities for FDA Commissioner Marty Makary.

By Luciana Borio and Phil Krause


Dismantling the one U.S. agency focused on older adults, people with disabilities is startlingly inefficient

ACL is a lean agency that supports older and disabled Americans through coordination and collaboration. It is the definition of efficiency.

By Alison Barkoff, Kathy Greenlee, Sharon Lewis, and Henry Claypool


Adobe

STAT+ | Promising signs for stem cell-based therapies for Parkinson’s in two new studies

Larger trials of allogeneic cells for Parkinson’s disease with more participants and additional features like blinding and placebo controls are crucial.

By Paul Knoepfler


The CDC’s critical occupational safety institute has been virtually wiped out

Restoration of NIOSH is essential to support industries critical to the country, from agriculture to manufacturing.

By Meghan F. Davis, Kirsten Koehler, Judy Bass, Julie Sorensen, and Gurumurthy Ramachandran


Why cats are so vulnerable to H5N1 bird flu

Veterinarian and epidemiologist Meghan F. Davis explains how little we know about the spread of H5N1 in cats — and why that’s so dangerous to humans.

By Torie Bosch


Adobe

STAT+ | No, I don’t want an AI scribe to write my pulmonologist’s note

A recent experience led one writer to think about why she so values her pulmonologist’s carefully written notes.

By Aliaa Barakat


The NIH called my health equity research ‘antithetical to scientific inquiry’

NIH letters canceling funding for health equity research contain six demonstrably false claims.

By Logan Beyer


STAT+ | Biotech investors: Stop expecting CRISPR science to make big leaps

CRISPR investors are looking for the big home-run hitters, while those with more modest scientific goals are, more often than not, the ones who deliver.

By Kelly Banas and Eric B. Kmiec


Adobe

STAT+ | ‘Most-favored nation’ drug pricing has three significant problems

“Most-favored nation” drug pricing can’t undo the basic economics of the global drug marketplace.

By Darius Lakdawalla and Dana P. Goldman


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

Enjoying First Opinion? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.